Oxidants downstream from superoxide inhibit nitric oxide production by vascular endothelium - A key role for selenium-dependent enzymes in vascular health

Medical Hypotheses

Volumn 53, Issue 4, 1999, Pages 315-325

  McCarty, M F ^a  

^a Nutrition 21   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; LIPID PEROXIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZING AGENT; PEROXIDE; PHOSPHATASE; PROTEIN; PROTEIN KINASE C; SELENIUM; SUPEROXIDE; THIOCTIC ACID; THIOL DERIVATIVE; THIOL GROUP; THIOREDOXIN REDUCTASE;

AMINO ACID BLOOD LEVEL; CARDIOVASCULAR RISK; CATABOLISM; DIABETIC NEUROPATHY; DRUG ACTIVITY; ENZYME ACTIVE SITE; HUMAN; OXIDATION; PRIORITY JOURNAL; REVIEW; SELENIUM DEFICIENCY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 0032732007     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0762     Document Type: Article

References (143)

1. Beckman J. S., Beckman T. W., Chen J. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci. 87:1990;1620-1624.
2. Mügge A, Elwell J. H., Peterson T. E., Harrison D. G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 260:1991;C219-C225.
3. Nakazone K., Watanabe N., Matsuno K. Does superoxide underlie the pathogenesis of hypertension. Proc Natl Acad Sci. 88:1991;10,045-10,048.
4. White C. R., Brock T. A., Chang L-Y. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci. 91:1994;1044-1048.
5. Lu X, Lie S-Y., Man R. Y. K. Enhancement of endothelium dependent relaxation in the rat aortic ring by selenium supplement. Cardiovasc Res. 28:1994;345-348.
6. Behne D., Kyriakopoulos A., Meinhold H., Köhrle J. Identification of type I iodothyronine 5′-deiodinase as a selenoenzyme. Biochem Biophys Res Comm. 173:1990;1143-1149.
7. Tamura T., Stadtman T. C. A new selenoprotein from human lung adenocarcinoma cells: puri?cation, properties, and thioredoxin reductase activity. Proc Natl Acad Sci. 93:1996;1006-1011.
8. Weitzel F., Wendel A. Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. J Biol Chem. 268:1993;6288-6292.
9. Bermano G., Arthur R. J., Hesketh J. E. Selective control of cytosolic glutathione peroxidase and phospholipid hydroperoxide glutathione peroxidase mRNA stability by selenium supply. FEBS Lett. 387:1996;157-160.
10. Upchurch G. R. Jr., Welch G. N., Fabian A. J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272:1997;17,012-17,017.
11. Tarkebaum G., Harlan J. M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest. 77:1986;1370-1376.
12. Munday R. Toxicity of thiols and disulphides: involvement of free-radical species. Free Rad Biol Med. 7:1989;659-673.
13. Bellamy M. F., McDowell I. F. W. Putative mechanisms for vascular damage by homocysteine. J Inher Metab Dis. 20:1997;307-315.
14. Stampfer M. J., Malinow M. R., Willett W. C. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US patients. J Am Med Assoc. 268:1992;877-881.
15. Boushey C. J., Beresford S. A. A., Omenn G. S., Motulsky A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc. 274:1995;1049-1057.
16. Mansoor M. A., Svardal A. M., Schneede J., Ueland P. M. Dynamic relation between reduced, oxidized, and protein-bound homocysteine and other thiol components in plasma during methionine loading in healthy men. Clin Chem. 38:1992;1316-1321.
17. Parthasarathy S. Oxidation of low density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta. 917:1987;337-340.
18. Van den Berg M., Boers G. H. J., Franken D. G. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest. 25:1995;176-181.
19. Bellamy M. F., Ramsey M. W., Brownlee M. Abnormal flow-mediated brachial artery responses in subjects with hyperhomocysteinaemia and low vitamin B12/folate status. J Inher Metab Dis. 19:1996;27.
20. Tawakol A., Omland T., Gerhard M. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation. 95:1997;1119-1121.
21. Lentz S. R., Sobey C. G., Peigors D. J. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 98:1996;24-29.
22. Stewart D. J., Pohl U., Bassenge E. Free radicals inhibit endothelium-dependent dilation in the coronary resistance bed. Am J Physiol. 255:1988;H765-H769.
23. Langenstroer P., Pieper G. M. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol. 263:1992;H257-H265.
24. Marczin N., Ryan U. S., Catravas J. D. Effects of oxidant stress on endothelium-derived relaxing factor-induced and nitrovasodilator-induced cGMP accumulation in vascular cells in culture. Circ Res. 70:1992;326-340.
25. Wolin M. S. Activated oxygen metabolites as regulators of vascular tone. Klin Wochenschr. 69:1991;1046-1049.
26. Zembowicz A., Hatchett R. J., Jakubowski A. M., Gryglewski R. J. Involvement of nitric oxide in the endothelium-dependent relaxation induced by hydrogen peroxide in the rabbit aorta. Br J Pharmacol. 110:1993;151-158.
27. Shimizu S., Saitoh Y., Yamamoto T., Momose K. Stimulation by hydrogen peroxide of L-arginine metabolism to L-citrulline coupled with nitric oxide synthesis in cultured endothelial cell. Res Commun Chem Pathol Pharmacol. 84:1994;315-329.
28. 2-induced vascular relaxation by endothelium-derived relaxing factor. Mol Cell Biochem. 149:1995;267-270.
29. Creager M. A., Gallagher S. J., Girerd X. J. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
30. Pieper G. M., Peltier B. A. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol. 25:1995;397-403.
31. Clarkson P., Adams M. R., Powe A. J. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994.
32. Wascher T. C., Posch K., Wallner S. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase. Biochem Biophys Res Comm. 234:1997;35-38.
33. Hishikawa K., Nakaki T., Suzuki H. L-arginine as an antihypertensive agent. J Cardiovasc Pharmacol. 20:1992;S196-S197.
34. Böger R. H., Bode-Böger S. M., Gerecke U., Frölich J. C. Long-term administration of L-arginine, L-NAME and the exogenous NO donor molsidomine modulate urinary excretion of nitrate and cGMP in rats - correlation with vascular reactivity. Cardiovasc Res. 28:1994;494-499.
35. Tsao P. S., McEvoy L. M., Drexler H. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation. 89:1994;2176-2182.
36. Mehta S., Stewart D. J., Langleben D., Levy R. D. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation. 92:1995;1539-1545.
37. Böger R. H., Bode-Böger S. M., Mügge A. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:1995;273-284.
38. Galley H. F., Thornton J., Howdle P. D. Combination oral antioxidant supplementation reduces blood pressure. Clin Sci. 92:1997;361-365.
39. Rubino A., Burnstock G. Recovery after dietary vitamin E supplementation of impaired endothelial function in vitamin E-deficient rats. Br J Pharmacol. 112:1994;515-518.
40. Rubino A., Loesch A., Goss-Sampson M. A. Effects of vitamin E de?ciency on vasomotor activity and ultrastructural organisation of rat thoracic aorta. Br J Pharmacol. 115:1995;415-420.
41. Raij L., Nagy J., Coffee K., DeMaster E. G. Hypercholesterolemia promotes endothelial dysfunction in vitamin E- and selenium-de?cient rats. Hypertension. 22:1993;56-61.
42. Matz J., Andersson T. L., Ferns G. A., Anggard E. E. Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit. Atherosclerosis. 110:1994;241-249.
43. Andersson T. L., Matz J., Ferns G. A., Anggard E. E. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis. 1111:1994;39-45.
44. Klemsdal T. O., Andersson T. L., Matz J. Vitamin E restores endothelium dependent vasodilatation in cholesterol fed rabbits: in vivo measurements by photoplethysmography. Cardiovasc Res. 28:1994;1397-1402.
45. Rosen P., Ballhausen T., Stockklauser K. Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. Diab Res Clin Pract. 31:1996;S143-S155.
46. Gilligan D. M., Sack M. N., Guetta V. Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol. 24:1994;1611-1617.
47. Busse R., Mülsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett. 265:1990;133-136.
48. Knowles R. G., Moncada S. Nitric oxide synthases in mammals. Biochem J. 298:1994;249-258.
49. Patel J. M., Block E. R. Sulfydryl-disulfide modulation and the role of disulfide oxidoreductases in regulation of the catalytic activity of nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol. 13:1995;352-359.
50. Patel J. M., Zhang J., Block E. R. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am J Respir Cell Mol Biol. 15:1996;410-419.
51. Buga G. M., Griscavage J. M., Rogers N. E., Ignarro L. J. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 73:1993;808-812.
52. Ziegler D. M. Role of reversible oxidation-reduction of enzyme thiols-disulfides in metabolic regulation. Ann Rev Biochem. 54:1985;305-329.
53. Fernando M. R., Nanri H., Yoshitake S. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur J Biochem. 209:1992;917-922.
54. Natarajan V., Scribner W. M., Taher M. M. 4-hydroxynonenal, a metabolite of lipid peroxidation, activates phospholipase D in vascular endothelial cells. Free Rad Biol Med. 15:1993;365-375.
55. Nataragan V., Taher M. M., Roehm B. Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty acid hydroperoxide. J Biol Chem. 268:1993;930-937.
56. Shasby D. M., Yorek M., Shasby S. S. Exogenous oxidants initiate hydrolysis of endothelial cell inositol phospholipids. Blood. 72:1988;491-499.
57. Weinheimer G., Wagner B., Osswald H. Interference of phorbolesters with endothelium-dependent vascular smooth muscle relaxation. Eur J Pharmacol. 130:1986;319-322.
58. Lewis M. J., Henderson A. H. A phorbol ester inhibits the release of endothelium-derived relaxing factor. Eur J Pharmacol. 137:1987;167-171.
59. Ryan U. S., Avdonin P., Hayes B., Broschat K. O. Signal transduction in endothelial cells. Ryan U., Rybanyi G. Endothelial Regulation of Vascular Tone. 1992;73-88 Marcel Dekker, New York.
60. Davda R. K., Chandler L. J., Guzman N. J. Protein kinase C modulates receptor-independent activation of endothelial nitric oxide synthase. Eur J Pharmacol. 266:1994;237-244.
61. Ohara Y., Sayegh H. S., Yamin J. J., Harrison D. G. Regulation of endothelial constitutive nitric oxide synthase by protein kinase C. Hypertension. 25:1995;415-420.
62. Matsubara T., Ziff M. Superoxice anion release by human endothelial cells: synergism between a phorbol ester and a calcium ionophore. J Cell Physiol. 127:1986;207-210.
63. Murphy H. S., Shayman J. A., Till G. O. Superoxide responses of endothelial cells to C5a and TNF-α: divergent signal transduction pathways. Am J Physiol. 263:1992;L51-L59.
64. Rodriguez-Martinez M. A., Martinez-Orgado J., Salaices M., Marin J. Impairment of acetylcholine relaxations by malondialdehyde, a marker of lipid peroxidation. J Vasc Res. 33:1996;463-470.
65. Tran K., Proulx P. R., Chan A. C. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity. Biochim Biophys Acta. 1212:1994;193-202.
66. Kunisaki M., Bursell S-E., Clermont A. C. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway. Am J Physiol. 269:1995;E239-E246.
67. Salmon J. A., Smith D. R., Flower R. J. Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta. 523:1978;250-262.
68. Ham E. A., Egan R. W., Soderman D. D. Peroxidase-dependent deactivation of prostacyclin synthetase. J Biol Chem. 254:1979;2191-2194.
69. Yokoyama M., Hirata K., Miyake R. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Comm. 168:1990;301-308.
70. Kugiyama K., Kerns S. A., Morrisett J. D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
71. Sugiyama S., Kugiyama K., Ohgushi M. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ Res. 74:1994;565-575.
72. Kugiyama K., Ohgushi M., Sugiyama S. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ Res. 71:1992;1422-1428.
73. Matsuda Y., Hirata K., Inoue N. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res. 72:1993;1103-1109.
74. Witztum J. L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
75. Bendich A., Machlin I. J., Scandurra O. The antioxidant role of vitamin C. Adv Free Rad Biol Med. 2:1986;419-444.
76. Levine G. N., Frei B., Koulouris S. N. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
77. Zhao B., Li X., He R. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophysics. 14:1989;175-185.
78. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 264:1989;13,963-13,966.
79. Bennett, B. G. Peterson, P. J. Assessment of human exposure to environmental selenium, Combs, G. F. JrSpallholz, J. E.Levander, O. A.Oldfield, J. E. Selenium in Biology and Medicine, Part B, Van Nostrand Reinhold, New York, 1987, 608, 618.
80. Wang Y X., Bocker K., Reuter H. Selenium and myocardial infarction: glutathione peroxidase in platelets. Klin Wochenschr. 59:1981;817-818.
81. Salonen J. T., Alfthan G., Huttunen J. K. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet. 2:1982;175-179.
82. Virtamo J., Valkeila E., Alfthan G. Serum selenium and the risk of coronary heart disease and stroke. Am J Epidemiol. 122:1985;276-282.
83. Oster O., Drexler M., Richard J. The serum selenium concentration of patients with acute myocardial infarction. Ann Clin Res. 18:1986;36-42.
84. Auzepy P., Blondeau M., Richard C. Serum selenium deficiency in myocardial infarction and congestive cardiomyopathy. Acta Cardiol. 42:1987;161-166.
85. Koehler H., Peter H. J., Pankau H., Duck H. J. Selenium in cardiology and angiology. Biol Trace Elem Res. 15:1988;157-166.
86. Kok F. J., Hofman A., Witteman J. C. Decreased selenium levels in acute myocardial infarction. J Am Med Assoc. 261:1989;1161-1164.
87. Beaglehole R., Jackson R., Watkinson J. Decreased blood selenium and risk of myocardial infarction. Int J Epidemiol. 19:1990;918-922.
88. Salonen J. T., Salonen R., Seppanen K. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. Br Med J. 302:1991;756-760.
89. Suadicani P., Hein H. O., Gyntelberg F. Serum selenium concentration and risk of ischaemic heart disease in a prospective cohort study of 3000 males. Atherosclerosis. 96:1992;33-42.
90. Buczyńnski A., Wachowicz B., Kedziora-Kornatowska K. Changes in antioxidant enzymes activities, aggregability and malonyldialdehyde concentration in blood platelets from patients with coronary heart disease. Atherosclerosis. 100:1993;223-228.
91. Edwards A. T., Blann A. D., Suarez-Mendez V. J. Systemic responses in patients with intermittent claudication after treadmill exercise. Br J Surg. 81:1994;1738-1741.
92. Thiele R., Schuffenhauer M., Winnefeld K. Selenium level in patients with acute myocardial infarct and in patients with severe angina pectoris without myocardial infarct. Med Klin. 90:1995;45-48.
93. Kardinaal A. F., Kok F. J., Kohlmeier L. Association between toenail selenium and risk of acute myocardial infarction in European men. The EURAMIC study. European Antioxidant Myocardial Infarction and Breast Cancer. Am J Epidemiol. 145:197;373-379.
94. Miettinen T. A., Alfthan G., Huttunen J. K. Serum selenium concentration related to myocardial infarction and fatty acid content of serum lipids. Br Med J. 287:1983;517-519.
95. Ringstad J., Thelle D. Risk of myocardial infarction in relation to serum concentrations of selenium. Acta Pharmacol Toxicol. 59:1986;336-339.
96. Kok F. J., de Bruijn A. M., Vermeeren R. Serum selenium, vitamin anti-oxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. Am J Clin Nutr. 45:1987;462-468.
97. Ringstad J., Jacobsen B. K., Thomassen Y., Thelle D. S. The Tromso Heart Study: serum selenium and risk of myocardial infarction a nested case-control study. J Epidemiol Comm Hlth. 41:1987;329-232.
98. Schaffer-Kronberger E., Eber B., Wawschinek O. Serum selenium levels in distinct manifestations of coronary artery disease. Acta Med Austriaca. 17:1990;22-24.
99. Salvini S., Hennekens C. H., Morris J. S. Plasma levels of the antioxidant selenium and risk of myocardial infarction among U.S. physicians. Am J Cardiol. 76:1995;1218-1221.
100. Salonen J. T., Salonen R., Ihanainen M. Blood pressure, dietary fats, and anti-oxidants. Am J Clin Nutr. 48:1988;1226-1232.
101. Longnecker M. P., Taylor P. R., Levander O. A. Selenium in diet, blood, and toenails in relation to human health in a seleniferous area. Am J Clin Nutr. 53:1991;1288-1294.
102. Clark L. C., Combs G. F. Jr., Turnbull B. W. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. J Am Med Assoc. 276:1996;1957-1963.
103. Yu S-Y., Zhu Y-J., Li W-G. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res. 29:1991;289-294.
104. Blot W. J., Li J-Y., Taylor P. R. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 85:1993;1483-1492.
105. Schiavon R., Freeman G. E., Guidi G. C. Selenium enhances prostacyclin production by cultured endothelial cells: possible explanation for increased bleeding times in volunteers taking selenium as a dietary supplement. Thromb Res. 34:1984;389-396.
106. Stead N. W., Bishop S. L., Carroll R. M. Selenium balance in the dependent elderly. Am J Clin Nutr. 39:1984;677.
107. Korpela H., Kumpulainen J., Jussila E. Effect of selenium supplementation after acute myocardial infarction. Res Comm Chem Pathol Pharmacol. 65:1989;249-252.
108. Brattstrom L. E., Israelsson B., Jeppsson J-O., Hultberg B. L. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 48:1988;215-221.
109. Ubbink J. B., van der Merwe A., Vermaak W. J. H., Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest. 71:1993;993-998.
110. Ubbink J. B., Vermaak W. J. H., van der Merwe A. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 124:1994;1927-1933.
111. Finkelstein J. D., Kyle W. E., Martin J. J., Pick A-M. Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Comm. 66:1975;81-87.
112. Selhub J., Miller J. W. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 55:1992;131-138.
113. Pick U., Haramaki N., Constantinescu A. Glutathione reductase and lipoamide dehydrogenase have opposite stereospecificities for α-lipoic acid enantiomers. Biochem Biophys Res Comm. 206:1995;724-730.
114. Arner E. S., Nordberg J., Holmgren A. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Comm. 225:196;268-274.
115. Packer L., Witt E. H., Tritschler H. J. Alpha-lipoic acid as a biological antioxidant. Free Rad Biol Med. 19:1995;227-250.
116. Handelman G. J., Han D., Tritschler H., Packer L. α-Lipoic acid reduction by mammalian cells to the dithiol form and release into the culture medium. Biochem Pharm. 47:1994;1725-1730.
117. Holmgren A. Thioredoxin catalyzes the reduction of insulin disul?des by dithiothreitol and dihydrolipoamide. J Biol Chem. 254:1979;9627-9632.
118. Spector A., Huang R-RC, Yan G-Z., Wang R-R. Thioredoxin fragment 31-36 is reduced by dihydrolipoamide and reduces oxidized protein. Biochem Biophys Res Comm. 150:1988;156-162.
119. Sachse G., Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm Metab Res. 9:1980;105-107.
120. Nagamatsu M., Nickander K. K., Schmelzer J. D. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care. 18:1995;1160-1167.
121. Ziegler D., Hanefeld M., Ruhnau K. J. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multi-centre randomized controlled trial (ALADIN Study). Diabetologia. 38:1995;1425-1433.
122. Stevens M. J., Dananberg J., Feldman E. L. The linked roles of nitric oxide, aldose reductase and (Na+, K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest. 94:1994;853-859.
123. Stevens M. J. Nitric oxide as a potential bridge between the metabolic and vascular hypotheses of diabetic neuropathy. Diabetic Med. 12:1995;292-295.
124. Serbinova E., Reznick S. K. A. Z., Packer L. Thioctic acid protects against ischemia-reperfusion injury in the isolated perfused Langendorff heart. Free Rad Res Comms. 17:1992;49-58.
125. Schönheit K., Gille L., Nohl H. Effect of α-lipoic acid and dihydrolipoic acid on ischemia/reperfusion injury of the heart and heart mitochondria. Biochim Biophys Acta. 1271:1995;335-342.
126. Baur A., Harrer T., Peukert M. Alpha-lipoic acid is an effective inhibitor of human immuno-de?ciency virus (HIV-1) replication. Klin Wochenschr. 69:1991;722-724.
127. Suzuki Y. J., Aggarwal B. B., Packer L. α-Lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochem Biophys Res Comm. 189:1992;1709-1715.
128. Makropoulos V., Brüning T., Schulze-Osthoff K. Selenium-mediated inhibition of transcription factor NF-κB and HIV-1 LTF promoter activity. Arch Toxicol. 70:1996;277-283.
129. McGregor P. E., Agrawal D. K., Edwards J. D. Attenuation of human leukocyte adherence to endothelial cell monolayers by tyrosine kinase inhibitors. Biochem Biophys Res Comm. 198:1994;359-365.
130. Anderson M. T., Staal F. J. T., Gitler C. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc Natl Acad Sci. 91:1994;11,527-11,531.
131. Guy G. R., Philp R., Tan Y. H. Activation of protein kinases and the inactivation of protein phosphatase 2A in tumour necrosis factor and interleukin-1 signal-transduction pathways. Eur J Biochem. 229:1995;503-511.
132. Weber C., Negrescu E., Erl W. Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. J Immunol. 155:1995;445-451.
133. Monteiro H. P., Ivaschenko Y. U., Fischer R., Stern A. Inhibition of protein tyrosine phosphatase activity by diamide is reversed by epidermal growth factor in fibroblasts. FEBS Lett. 295:1991;146-148.
134. Murphy H. S., Shayman J. A., Till G. O. Superoxide responses of endothelial cells to C5a and TNF-α: divergent signal transduction pathways. Am J Physiol. 263:1992;L51-L59.
135. Collins T. Endothelial neclear factor-κB and the initiation of the atherosclerotic lesion. Lab Invest. 68:1993;499-508.
136. Ferran C., Millan M. T., Csizmadia V. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Comm. 214:1995;212-223.
137. Khan S. G., Katiyar S. K., Agarwal R., Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res. 52:1992;4050-4052.
138. Sato Y., Nakatsuka H., Watanable T. Possible contribution of green tea drinking habits to the prevention of stroke. Tohoku J Exp Med. 157:1989;337-343.
139. Mukhtar, H. Katiyar, S. K. Agarwal, R. Cancer chemoprevention by green tea components, Jacobs, M. M. Diet and Cancer: Markers, Prevention, and Treatment, Plenum Press, New York, 1994, 123, 133.
140. Test S. T., Weiss S. J. The generation of utilization of chlorinated oxidants by human neutrophils. Adv Free Rad Biol Med. 2:1986;91-116.
141. Fliss H. Oxidation of proteins in rat heart and lungs by polymorphonuclear leukocyte oxidants. Mol Cell Biochem. 84:1988;177-188.
142. Schraufstätter I. U., Browne K., Harris A. Mechanisms of hypochlorite injury of target cells. J Clin Invest. 85:1990;554-562.
143. McCarty, M. F. The reported clinical utility of taurine in ischemic disorders may reflect a down-regulation of neutrophil activation and adhesion, 1997.